SCHEMBL5058134

SCHEMBL5058134

Cc1ccc([CH]CCc2ccc(C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.48
CYP1A2 P05177 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
IDO1 P14902 1/20 0.41
HRH3 Q9Y5N1 1/20 0.39
KCNH2 Q12809 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
GPR52 Q9Y2T5 1/20 0.39
IGF1R P08069 1/20 0.38
ALOX15 P16050 1/20 0.38
NFE2L2 Q16236 1/20 0.37
AGXT P21549 1/20 0.37
ACHE P22303 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091179 0.90 GPR52 (0.50) CYP2A6NPC1RAB9ASMN1; SMN2GPR52
SCHEMBL4608345 0.89 GRIN2D (0.43) CYP2A6CYP1A2TAAR1SMN1; SMN2CA1
SCHEMBL5056468 0.81 CYP2A6 (0.50) CYP2A6CYP1A2TAAR1IDO1NPC1
SCHEMBL28406079 0.79 NFE2L2 (0.50) CYP2A6CYP1A2TAAR1SMN1; SMN2IGF1R
SCHEMBL21179476 0.79 CYP2A6 (0.48) CYP2A6CYP1A2TAAR1IDO1NPC1
SCHEMBL7355796 0.77 ESR1 (0.56) TAAR1CA12CA1CA2CA9
SCHEMBL14880614 0.77 TAAR1 (0.48) TAAR1IDO1NFE2L2KMT2A
SCHEMBL1611178 0.76 CYP2A6 (0.50) CYP2A6IDO1NPC1RAB9ASMN1; SMN2
SCHEMBL8733231 0.76 CYP1A2 (0.52) CYP2A6CYP1A2TAAR1IDO1HRH3
SCHEMBL8476153 0.74 CYP1A2 (0.50) CYP2A6CYP1A2TAAR1IDO1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091945-B1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2014-01-15 EP claimed
EP-2091945-B1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2014-01-15 EP disclosed
US-8420684-B2 imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one PROBIODRUG AG (DE) 2013-04-16 US disclosed
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL CYP2A6 2242/4885CYP1A2 1934/4885TAAR1 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.